Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...(------ ----- Adjusted operati...),Health

Date:8/18/2009

------ ----- Adjusted operating income $9,238 $3,752 146% ====== ====== Adjusted operating income % 23.7% 9.8% Unallocated Reported operating loss $(9,569) $(10,513) -9% Write-off of in- process R&D - Diba acquisition - - Write-off of in- process R&D - Galpharm acquisition - - ----- ----- Adjusted operating loss $(9,569) $(10,513) -9% ======= ======== Fiscal Year ----------- 2009 2008 % Change ---- ---- --------- Consumer Healthcare Net sales $1,638,770 $1,336,140 23% Reported gross profit $460,133 $377,765 22% Inventory step-up - Unico 1,062 - Inventory step-up - Diba 1,503 - Inventory step-up - JB Labs 358 - Inventory step-up - Galpharm - 5,756 Impairment of fixed assets 1,600 - ----- ---- Adjusted gross profit $464,656 $383,521 21% ======== ======== Adjusted gross profit % 28.4% 28.7% Reported operating expenses $226,379 $205,111 10% Loss on asset exchange
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend